Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785641 | Bulletin du Cancer | 2017 | 8 Pages |
Abstract
Endometrial cancer has generally a good prognosis when diagnosed at an early stage, but remains incurable at an advanced stage (recurrent or metastatic) with only few therapeutic options. Hormonal therapy is the treatment of choice in case of slow progressive disease with a tumor expressing hormonal receptors due to its favorable safety profile. Taxanes, anthracyclines and platinum compounds are the most active chemotherapy agents with greater response rates when combined, though at the price of a significant toxicity. Targeted therapies based on a better understanding of tumor biology are being evaluated with some promising results. A good knowledge of patients' comorbidities, and exact histologic characteristics of the tumor (type, grade, hormonal receptor expression, and MSI status) for a well adapted therapeutic decision.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Patricia Pautier, Fanny Pommeret,